CD274 and cancer: Those with ongoing phase II or III trials in patients with cancer include the anti–PD-1 agents nivolumab, pembrolizumab (MK-3475), and pidilizumab (CT-011) and the anti–PD-L1 agent MPDL3280A (Table).